Commentary

Juvenile Myoclonic Epilepsy (JME) is classified as an idiopathic generalized epilepsy syndrome with "generalized polyspike and slow waves" on EEG. A number of clinical and electrophysiological studies in patients with JME, however, demonstrate alterations in specific cortical systems involving bilateral cortical and subcortical regions, including frontal lobe and anterior cingulate areas (1), motor cortex and supplementary motor areas (SMA) (2, 3), and thalamocortical pathways (4). JME has been associated with abnormalities in white matter pathways in the anterior internal capsule, especially in the anterior thalamic radiation fibers connecting the anterior thalamus with prefrontal cortical areas (4). Overall, these structural and functional studies support an emerging view that JME is a bilateral thalamocortical disorder with widespread cortical hyperexcitability, maximally involving the frontal lobe (1). JME, however, also appears to be a heterogeneous disorder with only mild abnormalities in tasks dependent on frontal lobe executive regions and variable PET/MRS and MRI abnormalities (5–7). One of the most striking abnormalities in cortical function in patients with JME has been increased cortical sensitivity to transcranial magnetic stimulation (TMS), particularly in anterior brain regions, following sleep deprivation (8) and during the morning hours (9). This increased sensitivity to transcranial evoked responses suggests abnormalities in intracortical inhibitory networks (10) and corresponds to the effectiveness of antiepileptic drugs (AEDs), which modulate GABA-mediated neurotransmission in treating JME (11).

Consistent with these findings, patients with JME often report that seizures are associated with stress (83% of patients) or sleep deprivation (77%), factors which can decrease intracortical inhibition (12). A smaller proportion of patients report that seizures may be associated with "thoughts and concentration" (23%) or hand activities (20%) (12). In a new study, Vollmar et al. used fMRI to explore how praxis ("the ideation or execution of complicated movements") activates cortical pathways in patients with JME and determined whether these pathways correspond to motor systems activated during myoclonic seizures (3). During performance of a visuospatial working memory task, patients with JME and
normal control subjects had activation of similar bilateral SMA regions and left central areas (corresponding to right-arm manual task responses). Test accuracy was similar for patients with JME and control subjects. Subtraction of a 0 memory/manual reaction condition identified activation of bilateral frontal and parietal areas associated with a visuospatial working memory network in both JME and control subjects (13). Compared with normal control subjects, however, patients with JME had increased motor cortex and SMA activation with increased memory task loads. Patients with recent seizures also had greater activation of motor cortex and SMA compared with patients with remote seizures. The authors concluded that this motor cortex coactivation, triggered by cognitive effort, explains myoclonic jerks and their facilitation through cognitive stressors.

Although Vollmar et al. demonstrated cognitive activation of motor and SMA regions involved in myoclonic seizures, praxis-induced seizures are uncommon in JME, even in untreated patients (14). Coactivation, though, may account for the rare association of JME with reflex reading seizures (15) and may engage mechanisms involved in photosensitivity. Vollmar et al. conclude more generally, however, that the SMA may have a specific role as relay for abnormal functional connectivity between the cognitive and motor system in JME patients and explain the provocative effect of cognitive activity on myoclonic jerks. While SMA and motor cortex are sources for jerk-linked spikes recorded in patients with progressive myoclonic epilepsies, polyspike bursts with myoclonic seizures in JME are generated from more widespread areas of cortex (16). It seems likely that cognitive activation and myoclonic seizures are both manifestations of widespread cortical hyperexcitability in JME.

Epigenetic mechanisms probably account for the development of cortical hyperexcitability and these clinical phenomena in JME. Polymorphisms in a gene coding an ACh receptor subunit—CHRNA4—are associated with susceptibility to JME in some patients (17), and with decreases in performance of visuospatial and phonological memory tasks in subjects without epilepsy (18). Mutations in the gene are associated with nocturnal frontal lobe epilepsy (19). These findings suggest that epigenetic mechanisms involving CHRNA4 and other genes may trigger the onset of seizures in late adolescence in patients with JME and produce the “cortical hyperexcitability” genes may trigger the onset of seizures in late adolescence in some patients (17), and with decreases in performance of visuospatial and phonological memory tasks in subjects without epilepsy (18). Mutations in the gene are associated with nocturnal frontal lobe epilepsy (19). These findings suggest that epigenetic mechanisms involving CHRNA4 and other genes may trigger the onset of seizures in late adolescence in patients with JME and produce the “cortical hyperexcitability” demonstrated by Vollmar et al. during cognitive activation and by others during myoclonic seizures.

by Gregory L. Krauss, MD

References
American Epilepsy Society

Epilepsy Currents Journal

Disclosure of Potential Conflicts of Interest

Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (DGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
Section #1  Identifying Information

1.  Today's Date: 12/8/2011

2.  First Name  Gregory    Last Name  Krauss  Degree MD

3.  Are you the Main Assigned Author?  ☒ Yes    ☐ No

   If no, enter your name as co-author:

4.  Manuscript/Article Title: Cognitive activation of "hyperexcitable cortex" in JME: can it trigger seizures?

5.  Journal Issue you are submitting for:  11.6

Section #2  The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>monitoring boards, statistical analysis, end point</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>committees, and the like</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>administrative support.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*  This means money that your institution received for your efforts on this study.

**  Use this section to provide any needed explanation.
Section #3 Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td></td>
<td></td>
<td>x</td>
<td>UCB Pharma, Vertex Laboratories, Eisai Laboratories</td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td></td>
<td></td>
<td>x</td>
<td>UCB Pharma, Sunovian, Eisai, Novartis, SK-Bioscience, Neuronex, NIH</td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation.</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

✓ No other relationships/conditions/circumstances that present a potential conflict of interest.
☐ Yes, the following relationships/conditions/circumstances are present:
Thank you for your assistance.

Epilepsy Currents Editorial Board